Condition
Ann Arbor Stage II Mantle Cell Lymphoma
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated1
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07444710Phase 1Not Yet RecruitingPrimary
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
NCT02494700Phase 2Active Not Recruiting
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
NCT02489123Phase 2Terminated
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Showing all 3 trials